About this trial
In France, the global prevalence of diabetes was estimated to 5% of the population in 2016, the type two diabetes (DT2) corresponding to 90% of cases. This number is widely underestimated because most people are untreated and undiagnosed. Due to the silent character of this disease, it is estimated that 20 à 30 % of diabetic adults have not yet been diagnosed. The conclusions, presented during the annual meeting of EASD in 2019, suggest that the precursor signs of this disease could be present until 20 years before the diagnosis.
Diabetes is a metabolic disease and people are diagnosed, in general, around 40-50 years old. The main risk factor of type II diabetes is lifestyle (rich diet, sedentary) but there is also other factors like hyperlipidemia, high blood pressure, high fasting blood sugar, stress, smoking, heredity, family history of diabetes, or gestational diabetes. This induces an increase of obesity, itself a major risk factor for type II diabetes occurrence.
From an economical aspect, chronic pathologies (including diabetes) represent 60% of health insurance expenses, even though it concerns 35% of insured persons, i.e. 20 million of patients. The average of annual reimbursement for a type 2 diabetic patient is 4890 euros. In this context, this study is the first step of thinking about a different, coordinated care approach, based on a preventive rather than curative approach.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Person with a FINDRISC score ≥ 10 points
Person who has given his/her express written and informed consent
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
Personalized care program
Other interventionIt includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
Treatment groups
Trial outcomes
Primary outcomes
Risk factors for type 2 diabetes in participants
Finnish Diabetes Risk Score (FINDRISC score) : 8 items with a total score from 0 to 26 points with 0 (no risk factor) and 26 (highest risk factor)
Secondary outcomes
Diabetes diagnostic
measuring fasting blood glucose
The Quality of Life
WHO questionary : total score out of 100, 26 questions with 5 likert scale items
program compliance
Compliance is based on all the scheduled visits, the number of visits not carried out and the time during the research will be described in each group.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: